A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)
Status:
Completed
Trial end date:
2021-10-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, placebo-controlled, parallel-arm, phase 2 study to
investigate the clinical efficacy, pharmacokinetics, and safety of CSL312 as prophylaxis to
prevent attacks in subjects with HAE.